2020年11月4日 · Lung cancer diagnoses are broken down into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC often starts in the bronchi, or the airways that lead from the trachea into the lungs and then branch off …

2025年2月22日 · Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung cancers are NSCLC. Only about 15% of lung...

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment.

2023年7月10日 · Lung cancer is histologically divided into 2 main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC comprises about 15% of lung cancer while NSCLC comprises approximately 85%.

About 80% to 85% of lung cancers are NSCLC. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells, are grouped together as NSCLC because their treatment and prognoses (outlooks) are often similar.

2021年2月25日 · 小细胞肺癌（SCLC）是一种高级别神经内分泌癌，主要在吸烟和既往吸烟者中发病，预后异常差1。 SCLC约占肺癌病例的15%。 其典型呼吸道症状包括咳嗽、呼吸困难或咯血，影像学表现为中央型肺肿物，常伴肿大的胸部淋巴结。 三分之二的患者在首次诊断时即出现远处转移。 最常见的转移部位包括对侧肺、脑、肝、肾上腺、骨。 与其易转移的特点相对应，SCLC是循环肿瘤细胞（circulating tumour cells, CTCs）浓度最高的几种实体肿瘤之一2（图1）。 尽 …

The 2 main types of lung cancer are small cell lung cancer (SCLC) and non-SCLC (NSCLC); NSCLC accounts for approximately 85% of all cases of lung cancer. 2,3 Regional incidence variations directly reflect smoking prevalence; specifically, the lowest and the highest incidences of lung cancer are found in Utah and Kentucky, where the lowest and ...

Learn the differences between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC makes up 80%-85% of lung cancers. SCLC metastasizes more quickly than NSCLC. Though similar tests diagnose both types of lung cancer, they are staged differently.

2024年5月23日 · 基于 IMpower010 研究的阿替利珠单抗于 2022 年 3 月 16 日获得 NMPA 批准，单药用于 PD-L1 阳性（TC ≥ 1%）、经手术切除、以铂类为基础化疗之后的 II-IIIA 期 NSCLC 患者的辅助治疗。 2.新增 II 级推荐：术后 II/III 期 NSCLC 进行 ALK 融合检测，指导辅助靶向治疗

肺癌包括非小细胞肺癌 (NSCLC)、小细胞肺癌（SCLC），其中NSCLC大约占肺癌总数的80％～85％，放射治疗是NSCLC、SCLC的治疗的重要手段，特别是局部晚期的NSCLC及全部的SCLC，是不可缺少的治疗。